NYD-SP18 Activators
NYD-SP18 activators belong to a chemical class of compounds that interact with biological systems in a highly specific manner. The name itself is indicative of a targeted approach, where "NYD-SP18" likely refers to a particular protein or molecular pathway that these activators influence. The "activator" designation within the compound's name suggests that these chemicals are not merely binding to their target but are also inducing an active change in its function, typically resulting in the upregulation or enhancement of the target's biological activity. The precise molecular structures of NYD-SP18 activators would be characterized by a set of functional groups that enable them to engage with their specific targets with high affinity and selectivity. These functional groups are often arranged in a three-dimensional configuration that is complementary to the active site or the allosteric site of the target molecule, akin to a key fitting into a lock.
The development and characterization of NYD-SP18 activators would have likely involved a sophisticated understanding of the molecular dynamics and biochemistry of the NYD-SP18 target. Researchers in the field of chemical biology and medicinal chemistry would utilize a range of techniques, such as high-throughput screening, computational modeling, and structure-activity relationship (SAR) studies to identify and optimize these activators. Through iterative cycles of design, synthesis, and testing, the chemical properties of NYD-SP18 activators are finely tuned to maximize their interaction with the target. Such properties include solubility, stability, and the ability to cross cellular membranes, which are crucial for the compound's interaction with its intracellular targets. Furthermore, the physical and chemical behaviors of these activators, such as their pharmacokinetics and metabolic pathways, would be of interest to chemists who strive to understand and predict how these compounds behave in different environments.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA (protein kinase A), which can then phosphorylate proteins that influence the functional activity of NYD-SP18 by altering its state of phosphorylation. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calcium-dependent protein kinases and phosphatases, potentially enhancing the phosphorylation status and activity of NYD-SP18. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC). PKC-mediated phosphorylation can modify various proteins and could enhance the functional activity of NYD-SP18 through phosphorylation-dependent mechanisms. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates PKA. Activation of PKA can lead to changes in phosphorylation and functional enhancement of NYD-SP18. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases 1 and 2A, which can increase the phosphorylation state of proteins by preventing dephosphorylation. This could indirectly enhance the phosphorylation and activity of NYD-SP18. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
Calcimycin is a calcium ionophore that increases intracellular calcium concentration, thus activating calcium-dependent kinases that could enhance the functional activity of NYD-SP18 through phosphorylation. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is an inhibitor of protein synthesis that can also activate JNK (c-Jun N-terminal kinase) signaling. JNK activation could modulate the activity of NYD-SP18 indirectly through phosphorylation of associated proteins or signaling cascades. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
Calmodulin is a calcium-binding messenger protein that activates various kinases and enzymes. Antagonists like W-7 can alter calmodulin activity, which might affect the functional activity of NYD-SP18 through changes in calcium signaling pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of PKC. By inhibiting PKC, this compound could shift the balance of phosphorylation states in the cell, potentially leading to an enhancement of NYD-SP18 activity through compensatory signaling mechanisms. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of the ERK pathway. By inhibiting MEK, U0126 may lead to alterations in the ERK pathway, possibly affecting other signaling pathways that enhance the activity of NYD-SP18. | ||||||